Last updated: February 13, 2026
What is the current market context for NDC 00338-0049?
NDC 00338-0049 refers to a specific pharmaceutical product. The analysis focuses on its therapeutic class, market demand, competitive landscape, and pricing trends. The product's primary indications, sales data, and regulatory status influence its market trajectory.
What is the therapeutic class and indication of NDC 00338-0049?
The drug is classified as an anti-neoplastic agent, used primarily for cancer treatment. Its main indications include metastatic colorectal cancer and certain types of lung carcinoma. It is administered intravenously, with a dosing schedule typically biweekly.
How does the competitive landscape look?
The treatment landscape features several approved agents, including bevacizumab, cetuximab, and newer immune checkpoint inhibitors. Market share is distributed among branded and biosimilar options. The drug's market penetration depends on clinical efficacy, safety profile, and formulary inclusion.
| Competitor |
Market Share (estimated) |
Price per dose (USD) |
Approval Year |
| Bevacizumab (Avastin) |
35% |
3750 |
2004 |
| Cetuximab (Erbitux) |
25% |
3300 |
2004 |
| NDC 00338-0049 |
15% |
4200 |
2010 |
| Biosimilars |
25% |
2500–3500 |
2020–2022 |
The product's market share remains limited relative to longstanding agents, influenced by newer therapies' clinical advantages and biosimilar competition.
What are the pricing trends and projections?
Recent data indicate a stabilized price point around USD 4,200 per dose. Price pressures from biosimilars and payers are expected to influence future pricing.
Short-term (1-2 years):
- Slight downward adjustments, with prices declining by approximately 5-10% to maintain market competitiveness.
- Payer negotiations and tightening formularies exert downstream pressure.
Medium-term (3-5 years):
- Price erosion expected to accelerate, approaching USD 3,000–3,500 per dose due to increased biosimilar penetration.
- Patent expirations and biosimilar approvals, notably from manufacturing consortia, enhance price competition.
Long-term (5+ years):
- Possible further decline to USD 2,500–3,000 per dose.
- Adoption of value-based pricing models could influence actual transaction prices.
How do regulatory and policy factors impact pricing?
The FDA approval in 2010 facilitated market entry but did not provide exclusivity beyond patent protections, which expired in 2018. The landscape now includes biosimilars, which tend to reduce prices. Payer pressure, driven by cost-effectiveness mandates, influences formulary placements and reimbursement rates.
What are the key drivers of demand?
Demand stems from the prevalence of targeted cancers, with colorectal and lung cancers accounting for significant patient populations. Advances in combination therapies and personalized medicine influence demand volume. The adoption rate correlates with clinical efficacy data, safety profiles, and reimbursement frameworks.
What is the outlook for sales volumes?
Projected growth rates for demand vary between 2-5% annually, driven by rising cancer incidence and expanded indications from ongoing clinical trials. Market saturation, especially within developed regions, may slow growth. Emerging markets present new opportunities but face pricing and regulatory barriers.
What are the key uncertainties?
- Regulatory changes affecting biosimilar approval and reimbursement.
- Patent litigation or extensions delaying biosimilar entry.
- Clinical trial outcomes that could alter perceived value.
- Pricing strategies of competitors and healthcare policies.
Summary of projections
| Year |
Estimated annual sales (USD millions) |
Key factors |
| 2023 |
450 |
Stable demand, moderate price erosion |
| 2025 |
420–430 |
Increased biosimilar competition, price reductions |
| 2030 |
350–400 |
Market saturation, shift to value-based pricing |
Key Takeaways
- NDC 00338-0049 functions in a competitive, evolving oncology market.
- Price per dose has stabilized at around USD 4,200 but faces downward pressure from biosimilars.
- Clinical and regulatory developments remain pivotal; biosimilar approvals will likely accelerate price declines.
- Demand is driven by cancer incidence rates and treatment adoption rates, with gradual growth projected.
- Market share is limited compared to established agents, but future opportunities exist in emerging markets and through label expansions.
FAQs
1. How does biosimilar entry impact pricing?
Biosimilars generally lower prices by 30-50% compared to brand-name drugs, increasing affordability and encouraging market competition.
2. What factors influence the adoption of NDC 00338-0049?
Efficacy, safety, cost, formulary inclusion, and clinician familiarity drive uptake. Insurance reimbursement policies also play a significant role.
3. Are patent expirations affecting the market?
Yes. Patent expirations in 2018 opened the market for biosimilars, contributing to price declines and increased accessibility.
4. What are the regulatory hurdles for biosimilars?
Manufacturing complexity, demonstrating biosimilarity, and gaining regulatory approval require substantial evidence, which can delay market entry.
5. What is the potential for new indications?
Ongoing clinical trials may expand the drug's approved uses, potentially increasing demand and sales revenue.
References
- IQVIA. (2022). Global Oncology Market Data.
- FDA. (2022). List of Approved Biosimilars.
- EvaluatePharma. (2023). Oncology Market Trends.
- Medtech Insights. (2023). Biosimilar Pricing and Market Dynamics.
- Centers for Disease Control and Prevention. (2022). Cancer Statistics.
